Form 4: Crinetics Pharmaceuticals CEO Richard Struthers Reports Gift of Common Stock
SEC Form 4 Filing
Richard Scott Struthers, President & CEO of Crinetics Pharmaceuticals, reports gifting 90,400 shares of common stock to both direct and indirect beneficiaries on May 14, 2025.
Summary
- On May 14, 2025, Richard Scott Struthers, the President & CEO of Crinetics Pharmaceuticals, executed a transaction involving the company's common stock.
- Struthers gifted 90,400 shares of common stock.
- Following the transaction, Struthers directly owns 320,017 shares.
- Struthers indirectly owns 661,205 shares through a family trust, 110,000 shares through Family Trust 2, 110,000 shares through Family Trust 3, 100,000 shares through Family Trust 4, and 1,000 shares through a spouse.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to a gift of stock. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their transactions involving the company's securities.
Stakeholder Impact
- The gift of shares may have a minor impact on the overall shareholder base, but is unlikely to be material.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date of the gift transaction of common stock. |
| 05/16/2025 | Date of signature for the Form 4 filing. |
Keywords
Crinetics Pharmaceuticals, Richard Scott Struthers, common stock, gift, beneficial ownership, Form 4, CRNX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.